Bipolar Depression

Risks & contraindications

Comparisons

Evidence quality

Other

Highlighted claims

• People with bipolar disorder spend most symptomatic time in depression. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
• About half of people with bipolar depressive episodes remain depressed at 6 months. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
• Depressive episodes in bipolar disorder create greater burden than manic episodes across several social, economic, and clinical domains. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
• Current recommended treatment options have limitations including modest efficacy, low tolerability, and poor acceptability. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
• Bipolar depression responds less effectively to conventional psychological interventions recommended for major depressive disorder. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol